Pharmaceutical product permissions

A searchable record of what Walter is equipped to evaluate.

Explore compositions across oral solids, oral liquids, sterile injectables, topical formats and selected specialist presentations. Use the catalogue to begin a technical and commercial discussion—not as a substitute for written facility-specific confirmation.

5,500Distinct records
21Dosage forms
407Sterile injectable records
17Therapeutic indexes

Built for portfolio teams

Move from a molecule search to a focused feasibility conversation.

The catalogue brings together composition, strength, pharmacological class, dosage form, manufacturing stream, BCS class and documented regulatory references. It also incorporates products listed in Walter’s March 2025 Injectables Manufacturing Profile. Therapeutic and pharmacological classes are practical navigation labels; final indication, regulatory position and site suitability are confirmed product by product.

Search the catalogue

Selected catalogue briefs

Explore a composition for your manufacturing brief.

Browse selected compositions by dosage form, then share the required strength, pack, quantities and target market for a product-specific feasibility review.

Search the full catalogue
Browse 26 selected composition briefs

Therapeutic index

Begin with the treatment area.

Each composition is assigned to one practical primary area for navigation. Combination products may span more than one clinical use and remain subject to product-specific review.

Searchable permissions catalogue

Find a composition, dosage form or capability route.

5,500distinct permission records

Loading full catalogue search…
Therapeutic area
Dosage-form family
Specific dosage form
Pharmacological class
Manufacturing stream
BCS classification
Confirmed CDSCO category
Drugs Rules status

24 records shown

Pain & musculoskeletal carePRM 1791
Dosage formLiquid injectables
Parenteral

Aceclofenac 150 mg / ml

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
NSAID analgesic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 140
Respiratory & allergyPRM 1792
Dosage formLiquid injectables
Parenteral

Acetylcysteine 1000 mg / 5 ml

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Mucolytic & expectorant
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Respiratory & allergyPRM 1793
Dosage formLiquid injectables
Parenteral

Acetylcysteine 400 mg / 2 ml

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Mucolytic & expectorant
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 1973
Dosage formDry-powder injectables
Parenteral

Acyclovir 250 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 1974
Dosage formDry-powder injectables
Parenteral

Acyclovir 500 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antiviral
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

CardiovascularPRM 1975
Dosage formDry-powder injectables
Parenteral

Adenosine 3000 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antiarrhythmic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Critical care & anaesthesiaPRM 1794
Dosage formLiquid injectables
Parenteral

Adrenaline 0.01 mg, Lignocaine 20 mg

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Critical-care agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 1795
Dosage formLiquid injectables
Parenteral

Alpha Beta-Arteether 150 mg / 2 ml

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Antimicrobial agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 1796
Dosage formLiquid injectables
Parenteral

Amikacin 100 mg / 2 ml

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Antimicrobial agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 1797
Dosage formLiquid injectables
Parenteral

Amikacin 250 mg / 2 ml

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Antimicrobial agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 1798
Dosage formLiquid injectables
Parenteral

Amikacin 500 mg

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Antimicrobial agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 638
Anti-infectivesPRM 5662
Dosage formLiquid injectables
Parenteral

Amikacin 500 mg / 10 ml

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Aminoglycoside antibiotic
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 1800
Dosage formLiquid injectables
Parenteral

Amikacin 500 mg / 2 ml

Route
Parenteral
Formulation type
Sterile liquid injectable
Pharmacological class
Antimicrobial agent
Manufacturing stream
Non-beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2080
Dosage formDry-powder injectables
Parenteral

Amoxycillin 1000 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antimicrobial agent
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2081
Dosage formDry-powder injectables
Parenteral

Amoxycillin 1000 mg, Clavulanic Acid 200 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antimicrobial agent
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2082
Dosage formDry-powder injectables
Parenteral

Amoxycillin 1000 mg, Sulbactam 500 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antimicrobial agent
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2083
Dosage formDry-powder injectables
Parenteral

Amoxycillin 1500 mg, Cloxacillin 1500 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Penicillin antibiotic
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 5988
Dosage formDry-powder injectables
Parenteral

Amoxycillin 1500 mg, Dicloxacillin 1500 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Penicillin antibiotic
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2085
Dosage formDry-powder injectables
Parenteral

Amoxycillin 200 mg, Clavulanic Acid 28.5 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antimicrobial agent
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 5989
Dosage formDry-powder injectables
Parenteral

Amoxycillin 2000 mg, Dicloxacillin 2000 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Penicillin antibiotic
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2087
Dosage formDry-powder injectables
Parenteral

Amoxycillin 2000 mg, Sulbactam 1000 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antimicrobial agent
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
CDSCO categoryFDC
Documented match

Listed in CDSCO FDC approval records

CDSCO filing reference · page 574
Anti-infectivesPRM 2088
Dosage formDry-powder injectables
Parenteral

Amoxycillin 250 mg

Same composition also available as

Tablets

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antimicrobial agent
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
CDSCO categoryNew Drug
Documented match

Listed in CDSCO New Drug approval records

CDSCO filing reference · page 619
Anti-infectivesPRM 2089
Dosage formDry-powder injectables
Parenteral

Amoxycillin 250 mg, Clavulanic Acid 50 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antimicrobial agent
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
Drugs Rules status
Schedule HList or category match
Regulatory pathwayProduct-specific review

Applicable central and/or state licensing requirements are confirmed against the composition, strength, dosage form and manufacturing unit before commercial commitment.

Anti-infectivesPRM 2090
Dosage formDry-powder injectables
Parenteral

Amoxycillin 3000 mg, Sulbactam 1500 mg

Route
Parenteral
Formulation type
Sterile powder for injection
Pharmacological class
Antimicrobial agent
Manufacturing stream
Beta-lactam
BCS class
N/A — Parenteral
CDSCO categoryFDC
Documented match

Listed in CDSCO FDC approval records

CDSCO filing reference · page 574

Explore the product catalogue

Browse product pages by therapeutic area.

Browse compositions, strengths and dosage forms for third-party and contract manufacturing enquiries. Each product page includes its catalogue specification, manufacturing and packaging considerations, and a product-specific enquiry link. Confirm the applicable unit, documents and commercial terms with Walter.

How to read this catalogue

Permission is a starting point—not a supply commitment.

01

Therapeutic index

Primary areas provide buyer-friendly navigation. Combination products may reasonably sit across several clinical categories.

02

Facility confirmation

Current licence scope, site allocation, equipment fit and applicable segregation requirements are checked before commitment.

03

Product feasibility

Formula, strength, presentation, pack, target market, testing requirements and commercial scale are assessed together.

04

Responsible use

This B2B catalogue is not prescribing information, patient guidance or a representation that every composition is currently available for sale.

Start the conversation

Found a composition worth discussing?

Use the enquiry link on any record to carry its composition and dosage form into your manufacturing brief.

Request a quote
Quick chat on WhatsAppLet’s discuss your product